hsa-miR-521: Hsa-mir-521 is a microRNA that has been studied in various contexts. It is one of the qPCR primers used in the Qiagen miScript Primer Assay [PMC4600756]. In gastric cancer, hsa-mir-521 has been identified as a target of ERCC8 [PMC7354774]. In ovarian cancer, hsa-mir-521 has been associated with tumor grade-dependent survival, with lower expression being associated with lower survival probability in high-grade tumors [PMC3595291]. Hsa-mir-521, along with hsa-miR-381, has also been found to be overexpressed in platinum-resistant ovarian cancer [PMC3595291]. In prostate cancer cells, the expression levels of hsa-mir-521 were found to be altered after radiation treatment [PMC3424689]. Additionally, hsa-mir-521 was down-regulated by H2O2 treatment in a study on oxidative stress [PMC6884596]. Consensus expression distributions were observed for hsa-miR-519a and hsa-mir-521 across different samples [PMC3120834]. References: [PMC4600756] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600756/ [PMC7354774] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354774/ [PMC3595291] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595291/ [PMC3424689] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424689/ [PM6884596] - https://www.ncbi.nlm.nih.gov/pmc/articles/PM6884596/ [PM3120834] - https://www.ncbi.nlm.nih.gov/pmc/articles/PM3120834/